Gujarat Themis Biosyn's credit ratings were placed on 'Rating Watch with Negative Implications' due to acquisition-led leverage risk. The company formally dissented, citing a backward-looking agency view and plans for a ₹1,000 crore QIP.
Gujarat Themis Biosyn Faces Credit Rating Watch with Negative Implications
Gujarat Themis Biosyn's credit ratings have been placed on 'Rating Watch with Negative Implications' by CARE, with current ratings at CARE BBB (RWN) and CARE A3+ (RWN).
Reader Takeaway: Acquisition leverage risk due to large planned acquisitions; management disputes rating agency's forward-looking assessment.
What just happened
Credit rating agency CARE has placed Gujarat Themis Biosyn Limited's ratings on a watch with negative implications. The agency cited significant risks associated with the company's planned acquisitions, specifically the acquisition of MicroBiopharm Japan Co. for ¥1.5 Billion and an anti-infective portfolio from Sanofi for €158 million. These acquisitions, relative to the company's tangible net worth, are seen as posing significant leverage risk, coupled with uncertainty surrounding the funding structure. Consequently, overall gearing is projected to rise to 0.56x in FY26 from 0.12x in FY25, and interest coverage is expected to drop sharply to 26.09x from 193.27x.
Why this matters
This rating action signals potential financial instability and credit concerns for Gujarat Themis Biosyn. The 'Rating Watch with Negative Implications' indicates that the agency foresees a possible downgrade, which could impact the company's ability to secure future financing on favorable terms. The disagreement between the company and the rating agency highlights a critical juncture for investors, who must assess the execution risk of the company's growth strategy against the highlighted financial pressures.
The backstory
Gujarat Themis Biosyn has a history of operations in the biosynthetics and pharmaceuticals sector. The company is undertaking a significant expansion through inorganic means, aiming to enhance its market position and product portfolio. This aggressive growth strategy has now brought it under scrutiny from credit rating agencies due to the substantial debt leverage involved.
What changes now
The company has formally dissented against the rating agency's decision, arguing that the assessment is 'overly backward-looking' and does not account for its robust liquidity buffers or its concrete plan to raise ₹1,000 crore via a Qualified Institutional Placement (QIP). The company's management has instructed that its counter-arguments be published alongside the rating rationale, indicating a strong disagreement over the financial outlook.
Risks to watch
The primary risks revolve around the execution of the QIP to raise ₹1,000 crore, which is critical for funding the acquisitions and mitigating leverage. The successful integration of acquired entities and their ability to generate sufficient EBITDA to offset the increased leverage are also key watch points. Additionally, any indirect encumbrance on promoter shares remains a monitorable governance and liquidity concern.
Peer comparison
While specific peer data isn't provided in the filing, companies undertaking large, debt-funded acquisitions often face similar scrutiny regarding leverage and funding. Pharmaceutical and biotech firms that expand rapidly through M&A typically see increased financial risk until the acquired assets prove their accretive value.
Context metrics (time-bound)
- Total Operating Income: Grew by 9.81% year-on-year to ₹167.23 crore in FY26.
- PBILDT Margin: Remained healthy at 46.01% in FY26.
- Gross Current Assets Period: Elongated to 205 days in FY26 from 99 days in FY25, attributed to increased collection and inventory periods.
What to track next
Investors should closely monitor the progress and success of the ₹1,000 crore QIP, as this is crucial for validating the acquisition funding plan. The company's ability to manage its increased debt levels, integrate the acquired businesses effectively, and demonstrate improved financial metrics will be key to watch for any potential rating changes.